The SERENA study
The SERENA study is a large academic, multicenter study investigating whether Ozempic® (semaglutide) can prevent type 2 diabetes after a recent history of gestational diabetes. This project is coordinated by UZ Leuven with Prof. Dr. Katrien Benhalima as principal investigator, in collaboration with 13 Belgian centers: UZ Leuven, AZORG, UZA, UZ Brussel, AZ Groeninge Kortrijk, ZAS, Erasme, CHU de Liège, Centre Hospitalier de Mouscron, Vitaz Sint-Niklaas, AZ Sint-Jan Brugge, Jan Yperman and AZ Turnhout.
What is the SERENA study about?
Semaglutide is used to treat people with type 2 diabetes. In people with type 2 diabetes, treatment with semaglutide can lower sugar levels, leads often to weight loss and can reduce the risk for cardiovascular diseases. Women with prediabetes diagnosed during the postpartum oral glucose tolerance test (OGTT) have a risk of 50% to develop type 2 diabetes within the 5 years following the delivery.
The SERENA project is investigating whether we can prevent type 2 diabetes with the medication Ozempic® in women who have elevated sugar levels (prediabetes) after a recent pregnancy with gestational diabetes.
Participating centers of the SERENA study
Partners of the SERENA study
Sponsors of the SERENA study
